Scholar Rock Holding Corporation: Revision history

20 August 2022

• curprev 16:5216:52, 20 August 2022 95.149.241.133 talk 1,127 bytes +11 No edit summary undo

14 August 2022

• curprev 01:4401:44, 14 August 2022 109.180.50.163 talk 1,116 bytes +15 No edit summary undo

31 July 2022

• curprev 07:2507:25, 31 July 2022 >Chris 1,101 bytes +1,101 Created page with "Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of c..."